Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 7,084 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Tomosynthesis digital mammography imaging system; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts + 2 more

Conditions: Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions: suramin, paclitaxel, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Bevacizumab, Standard adjuvant chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more

Conditions: Breast Cancer
Interventions: Brief supportive-expressive group therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1998
U.S. locations: 10
States / cities: Wichita, Kansas • Kalamazoo, Michigan • Saint Louis Park, Minnesota + 7 more

Conditions: Early Stage Breast Carcinoma, Dyspnea
Interventions: Inspiratory muscle training; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: BRCA1/2 Negative
Interventions: Questionnaires; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer Survivors
Interventions: Transcranial Direct Current Stimulation (tDCS), Questionnaires; Device · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma
Interventions: Metformin Hydrochloride, Doxycycline; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Biospecimen Collection, Fisetin, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Alhambra, California • Beverly Hills, California • Burbank, California + 4 more

Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Interventions: LNCB74; Drug
Lead sponsor: LigaChem Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Newport Beach, California • Edgewood, Kentucky • Boston, Massachusetts + 12 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Arthralgia
Interventions: Not listed
Lead sponsor: Lynn Henry; Other
Eligibility: 21 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Interventions: entinostat, anastrozole, diagnostic laboratory biomarker analysis, therapeutic conventional surgery; Drug · Other · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Hot Flashes
Interventions: acupuncture therapy, hot flashes attenuation, management of therapy complications; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: CyberKnife Partial Breast Irradiation; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 45 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging (MBI), Tc99m sestamibi; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Cisplatin, carboplatin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more

Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Interventions: ALTA2618; Drug
Lead sponsor: Alterome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: La Jolla, California • Denver, Colorado • Sarasota, Florida + 7 more

Conditions: Breast Cancer
Interventions: perform dynamic contrast enhanced (DCE) MRI; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin; Drug · Other · Procedure + 1 more
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 3,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 480
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more

Conditions: Breast Cancer
Interventions: First Sense Medical®; Device
Lead sponsor: First Sense Medical, LLC; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Interventions: Atezolizumab, Tivozanib; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Malignant Melanoma, Breast Cancer
Interventions: T cells modified with RNA anti -cMET CAR; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

Group Therapy for Primary Breast Cancer

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy

Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Brain Imaging, Nutrition, and Cognition in Breast Cancer Survivors

Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Acupuncture in Treating Hot Flashes in Women With Breast Cancer

A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast

Tc99m Sestamibi Molecular Breast Imaging

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Quantitative Dynamic Contrast Enhanced Breast MRI

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)